Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...

Nexviazyme (avalglucosidase alfa) for treating Pompe Disease. This recommendation is for both infantile onset Pompe (IOPD) and Late onset Pompe (LOPD). Until now, only infants have been eligible ...

The drug was registered in the US last year as Nexviazyme. It is an updated version of Sanofi's blockbuster Myozyme/Lumizyme (alglucosidase alfa) therapies for Pompe, but is designed to be more ...

Her son is on Nexviazyme and used to be on Lumizyme, neither of which come from Canada. There is also not an alternative for these medications, she told the council. Meghan Dudenhoeffer said she ...

Outside of the US, we're seeing patients from all three segments, some switching from Myozyme and from Nexviazyme at a proportional rate to the respective market shares and some from the naive ...